Zejula for Ovarian cancer maintenance
Quick answer: Zejula is used for Ovarian cancer maintenance as part of a parp inhibitor treatment regimen. Poly(ADP-ribose) polymerase 1/2 inhibitor causing synthetic lethality in BRCA-deficient tumor cells The specific dosing for Ovarian cancer maintenance is determined by your prescriber based on individual factors.
Why is Zejula used for Ovarian cancer maintenance?
Zejula belongs to the PARP inhibitor class. Poly(ADP-ribose) polymerase 1/2 inhibitor causing synthetic lethality in BRCA-deficient tumor cells This action makes it useful for treating or managing Ovarian cancer maintenance in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Zejula is the right choice for a specific patient depends on the type and severity of Ovarian cancer maintenance, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Ovarian cancer maintenance
Common adult dosing range: 200-300 mg orally once daily. The actual dose for Ovarian cancer maintenance depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Zejula medicine page.
What to expect
Zejula treatment for Ovarian cancer maintenance typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Ovarian cancer maintenance
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Zejula is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all PARP inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Zejula
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Zejula full prescribing information · All PARP inhibitor alternatives
Frequently asked questions
How effective is Zejula for Ovarian cancer maintenance?
Effectiveness varies by individual response, dose, and severity. Zejula is one of several treatment options for Ovarian cancer maintenance, supported by clinical evidence within the parp inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Zejula for Ovarian cancer maintenance?
Treatment duration depends on the nature of Ovarian cancer maintenance — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Zejula when used for Ovarian cancer maintenance?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Zejula for Ovarian cancer maintenance?
Yes. Multiple medicines and non-drug options exist for Ovarian cancer maintenance. Alternatives within the parp inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.